Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lasmiditan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F known ✓ | P30939 | 19/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | HTR1B | P28222 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lasmiditan SCHEMBL29376817 | 1.00 | HTR1F (1.00) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| Lasmiditan SCHEMBL2536468 | 0.99 | HTR1F (0.98) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| Lasmiditan SCHEMBL29598155 | 0.99 | HTR1F (0.98) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| Lasmiditan SCHEMBL25337411 | 0.97 | HTR1F (0.94) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| Lasmiditan SCHEMBL23716695 | 0.94 | HTR1F (0.89) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL2537137 | 0.92 | HTR1F (0.85) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL30730002 | 0.92 | HTR1F (0.85) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL2541484 | 0.90 | HTR1F (0.81) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL2539164 | 0.89 | HTR1F (0.79) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL29031450 | 0.88 | HTR1F (0.79) | HTR1FCHRM5DRD5HTR1DHTR1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250271426-A1 | REDUCTION OF BITTER TASTE OF ACTIVE PHARMACEUTICAL INGREDIENTS AND RELATED ASSAYS AND SCREENING METHODS | FIRMENICH INCORPORATED (US) | 2025-08-28 | — | — | US | claimed |
| US-20250228839-A1 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | COLUCID PHARMACEUTICALS, INC. | 2025-07-17 | — | — | US | claimed |
| US-12257246-B2 | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide | COLUCID PHARMACEUTICALS, INC. (US) | 2025-03-25 | — | — | US | claimed |
| EP-4493928-A1 | REDUCTION OF BITTER TASTE OF ACTIVE PHARMACEUTICAL INGREDIENTS AND RELATED ASSAYS AND SCREENING METHODS | Firmenich Incorporated (US) | 2025-01-22 | — | — | EP | claimed |
| US-12138254-B2 | Chronic nightly dosing of lasmiditan for migraine prevention | ELI LILLY AND COMPANY (US) | 2024-11-12 | — | — | US | claimed |
| US-11939301-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2024-03-26 | — | — | US | claimed |
| US-20240059666-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2024-02-22 | — | — | US | claimed |
| EP-4279132-A2 | CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION | Eli Lilly and Company (US) | 2023-11-22 | — | — | EP | claimed |
| WO-2023205647-A1 | REDUCTION OF BITTER TASTE OF ACTIVE PHARMACEUTICAL INGREDIENTS AND RELATED ASSAYS AND SCREENING METHODS | FIRMENICH INCORPORATED (US) | 2023-10-26 | — | — | WO | claimed |
| EP-3846810-B1 | CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION | LILLY CO ELI (US) | 2023-10-18 | — | — | EP | claimed |
| EP-2413933-A2 | COMPOSITION OF 2,4,6-TRIFLUORO-N-Ý6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL¨-BENZAMIDE | Colucid Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| WO-2011123654-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS OF PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS | COLUCID PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| WO-2010115125-A2 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | COLUCID PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-20100256187-A1 | COMPOSITION OF 2,4,6- TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | COLUCID PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | claimed |
| US-7423050-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | claimed |
| EP-1841427-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | Pozen, Inc. (US) | 2007-10-10 | — | — | EP | claimed |
| EP-1492786-B1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2006-10-04 | — | — | EP | claimed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | claimed |
| WO-2006081127-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | POZEN INC. (US) | 2006-08-03 | — | — | WO | claimed |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | ELI LILLY AND COMPANY | 2005-10-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256187-A1 | COMPOSITION OF 2,4,6- TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | PDGFRA, SLCO1A2, SLCO2A1 | HTR1F 193/4885CHRM5 607/4885DRD5 2313/4885 |
| US-12257246-B2 | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide | PDGFRA, SLCO1A2, SLCO2A1 | HTR1F 232/4885CHRM5 617/4885DRD5 2390/4885 |
| US-11939301-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | HTR1F, HTR1A, TFAM | HTR1F 1/4885CHRM5 1605/4885DRD5 774/4885 |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | HTR1F 1/4885CHRM5 768/4885DRD5 457/4885 |
| US-20240059666-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | HTR1F 275/4885CHRM5 304/4885DRD5 2716/4885 |
| US-12138254-B2 | Chronic nightly dosing of lasmiditan for migraine prevention | LPXN, CNR2, HCRTR2 | HTR1F 203/4885CHRM5 810/4885DRD5 427/4885 |
| US-20250228839-A1 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | PDGFRA, SLCO1A2, SLCO2A1 | HTR1F 193/4885CHRM5 607/4885DRD5 2313/4885 |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | HTR1F, HTR1A, HTR1E | HTR1F 1/4885CHRM5 239/4885DRD5 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.